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This study aims to investigate the effect of Bifidobacterium adolescentis against
noroviruses (NoVs). Murine norovirus-1 (MNV-1) used as a surrogate was detected
by plaque assay and RT-qPCR. Human NoV virus like particles (VLPs) were detected
by cell-binding assay. It was shown that the presence of B. adolescentis could inhibit
the multiplication of MNV-1 on RAW 264.7 cells within 48 h of co-incubation period
at 37◦C. This inhibition did not occur at the viral binding stage, as no difference was
observed in MNV-1 genomic copies collected from washed RAW 264.7 cells without
and with B. adolescentis after co-incubation for 1 h at room temperature. Meanwhile,
the presence of B. adolescentis decreased the binding of human NoV GI.1 VLPs to
both Caco-2 cells and HT-29 cells, while no reduction was induced for the binding of
human NoV GII.4 VLPs to Caco-2 cells.
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INTRODUCTION
Probiotics are defined as “living micro-organisms, which upon ingestion in certain numbers,
exert health benefits beyond inherent basic nutrition.” Most probiotic microorganisms belong
to lactic acid bacteria (LAB), such as Lactobacillus sp., Bifidobacterium sp., and Enterococcus sp
(Ljungh and Wadström, 2006). Probiotics may benefit the human and animal host directly, by
preventing the infection and combating the causative agent of the intestinal disorder, or indirectly,
by balancing the disrupted equilibrium of the enteric flora and augmenting the host’s immune
responses (Maragkoudakis et al., 2010; Sanders et al., 2013). Clinical evidence has reported that
feeding of probiotics can prevent effectively for diarrhea and shedding of rotavirus (Saavedra
et al., 1994; Van Niel et al., 2002; Sazawal et al., 2006; Grandy et al., 2010). Accordingly, with the
use of animal models, multiple probiotic strains have shown anti-rotavirus effect (Muñoz et al.,
2011; Kandasamy et al., 2014; Mao et al., 2016). In addition, in vitro studies have demonstrated
that probiotics may have antiviral activity against rotavirus (Maragkoudakis et al., 2010; Muñoz
et al., 2011), coxsackievirus (Kim et al., 2014), hepatitis C virus (El-Adawi et al., 2015), as well as
noroviruses (NoVs; Aboubakr et al., 2014; Rubio-del-Campo et al., 2014).
Noroviruses, one genera of the Caliciviridae family, were reported as the cause of between 73%
to greater than 95% of global epidemic nonbacterial gastroenteritis outbreaks and approximately
half of all gastroenteritis outbreaks (Atmar and Estes, 2006). Although NoV infections are generally
mild, it may require hospital care and can be associated with mortality in elderly, chronically ill or
immune-compromised patients. Taking into consideration their widespreadness, NoVs are causing
heavy disease burdens associated with large economic losses (Van Beek et al., 2013). Despite recent
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progress, several key challenges remain in assessing the efficacy of
vaccines and antiviral drugs for human NoV infection, such as the
lack of a robust cell culture system or animal model limits direct
study of these viruses, and the extreme genetic heterogeneity
among strains (Karst et al., 2014). Therefore, it is of high interest
to investigate further if probiotics can be employed for NoV
control and treatment.
In this study, due to the non-cultivability of human NoVs,
murine norovirus-1 (MNV-1, a very commonly used human
NoV surrogate, Kniel, 2014), and human NoV virus like




Bifidobacterium adolescentis (LMG10502, biological origin: adult
intestines) was obtained from Belgian Coordinated Collection
of Microorganisms (BCCM/LMG). B. adolescentis was cultured
in tryptone soya broth (TSB, Oxoid, Thermo) at 37◦C.
The anaerobic atmosphere was generated with the use of
ANAEROGENTM COMPACT (Oxoid, Thermo).
Before each experiment, B. adolescentis were cultured for 48 h,
normalized to an OD570 of 0.4, and washed twice with phosphate
buffered saline (PBS, pH 7.4).
Cell Lines, Virus, and Virus-Like Particles
(VLPs)
Cells of the murine macrophage cell line RAW 264.7 (ATCC
TIB-71; kindly provided by Prof. H. W. Virgin, Washington
University School of Medicine, St. Louis, MO, USA) were
maintained in complete DMEM medium and grown at 37◦C
under a 5% CO2 atmosphere. Complete DMEM consisted
of Dulbecco’s modified Eagle’s medium (DMEM; Lonza,
Walkersville, MD, USA) containing 10% low-endotoxin fetal
bovine serum (HyClone, Logan, UT, USA), 100 U/ml penicillin,
100 µg/ml streptomycin (Lonza), 10 mM HEPES (Lonza), and
2 mM L-glutamine (Lonza).
RAW 264.7 cells were infected with MNV-1.CW1 and
passaged seven times at a multiplicity of infection (MOI) of
0.05 (MNV-1:cells) for 2 days. After two freeze-thaw cycles, low
speed centrifugation was used to remove cellular debris from the
virus suspension, as described by Wobus et al. (2004). The lysate
containing suspended MNV-1 was stored in aliquots at –75◦C.
Cell line Caco-2 (ECACC 86010202) was cultured in
Eagle’s minimum essential medium with Earle’s salts (EMEM;
Lonza) supplemented with 10% low-endotoxin fetal bovine
serum (HyClone), 100 U/ml penicillin, 100 µg/ml streptomycin
(Lonza), and 2 mM L-glutamine (Lonza) and grown at 37◦C
under a 5% CO2 atmosphere. HT-29 (ATCC HTB-38) cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM;
GIBCO R©, Life Technologies.) supplemented with 10% low-
endotoxin fetal bovine serum (GIBCO R©, Life Technologies),
100 U/ml penicillin, 100 µg/ml streptomycin (GIBCO R©,
Life Technologies), and 2 mM L-glutamine (GIBCO R©, Life
Technologies) and grown at 37◦C under a 5% CO2 atmosphere.
Virus-like particles of human NoV GI.1 (Norwalk virus)
and GII.4 (Dijon 1996) were generated using a previously
described method (Jiang et al., 1992). Recombinant baculoviruses
containing the VP1 protein from NoV GI.1 and GII.4 were
generated, and VLPs were produced by infection of Hi5 insect
cells. VLPs were released from the infected Hi5 cells by three
rounds of freeze-thawing and then clarified by removal of cellular
debris (6,000 × g for 30 min) and baculovirus (14,000 × g
for 30 min). The VLPs were partially purified through a 30%
(wt/vol) sucrose cushion in TNC buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 10 mM CaCl2) containing the protease
inhibitor leupeptin at 150,000 × g for 2 h. The pelleted VLPs
were resuspended in TNC and further purified by isopynic
centrifugation in cesium chloride (150,000 × g; 18 h). The
resultant VLP bands were collected by puncture, and the solution
containing VLPs was dialyzed against PBS prior to quantification
by bicinchoninic acid (BCA) protein assay (Thermo Scientific)
and stored at –80◦C.
Cytotoxicity Test-Neutral Red Assay
The cytotoxicity of bacteria on RAW 264.7 cells was measured
by a neutral red assay based on the description by Fotakis and
Timbrell (2006) with a few modifications. The RAW 264.7 cells
were seeded into 96-well plates at a density of 105 viable cells per
well. On the following day, the RAW 264.7 cells were washed with
PBS to remove the antibiotics, the B. adolescentis re-suspended in
DMEM (Lonza) were added onto the cells (50 µl per well) and
incubated for 1 h at room temperature. Afterward the inoculum
was aspirated and fresh complete DMEM without antibiotics was
added (100 µl per well). Plates were incubated at 37◦C and 5%
CO2.
After 2 days incubation, the medium of the cells was
changed to neutral red dye (Sigma–Aldrich, St. Louis, MO, USA,
100 µg/ml) dissolved in DMEM (100 µl per well) and incubated
for another 2 h at 37◦C and 5% CO2. Cells were then washed
with PBS and the addition of elution medium (EtOH/AcCOOH,
50%/1%, 100µl per well) followed by gentle shaking for 10 min so
that complete dissolution was achieved. The optical density was
read at 540 nm (OD540).
Viral Multiplication Inhibition Test on
MNV-1 Detected by Plaque Assay
The RAW 264.7 cells were seeded into six-well plates at a density
of 2 × 106 viable cells per well. On the following day, the
B. adolescentis re-suspended in DMEM (Lonza) was used to make
ten-fold dilutions from MNV-1 lysate. The RAW 264.7 cells
were washed with PBS to remove the antibiotics, the mixture of
bacteria and MNV-1 was added onto the cells (500 µl per well,
two wells per sample). Plates were incubated for 1 h at room
temperature and manually rocked every 15 min before aspirating
the inoculum and overlaying the cells with 1.5% SeaPlaque
agarose (Cambrex, Rockland, ME, USA) in MEM (Lonza)
supplemented with 10% low-endotoxin fetal bovine serum, 1%
HEPES, 1% penicillin/streptomycin, and 2% glutamine (complete
MEM) per well. Plates were incubated at 37◦C and 5% CO2
for 2 days. To visualize plaques, cells were stained with 1.5%
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SeaKem agarose in complete MEM containing 1% neutral red
(Sigma–Aldrich) per well for 6 h.
Plaque sizes were shown to be associated with the virulence
in multiple studies (Takemoto, 1966; Lipton, 1980). In this study,
from photos taken from each group with the same format and
size, the diameters of plaques were measured and recorded by
the use of ImageJ (National Institutes of Health, Bethesda, MD,
USA).
Viral Binding Inhibition Test on MNV-1
Detected by RT-qPCR
The RAW 264.7 cells were seeded into 96-well plates at a
density of 105 viable cells per well. On the following day,
the B. adolescentis was re-suspended in MNV-1 dilutions with
DMEM (50 µl per sample, with 5.8 ± 0.1 log MNV-1 genomic
copies per sample). The RAW 264.7 cells were washed with PBS
to remove the antibiotics, the mixture of bacteria and MNV-1
were added onto the cells (50 µl per well) and incubated for 1 h
at room temperature. Afterward the inoculum was aspirated and
the cells were washed by PBS for three times.
The RNAs of washed cells were extracted by using the RNeasy
Mini kit (Qiagen, Hilden, Germany). For each sample the 100 µl
PBS was firstly mixed with 350µl lysis buffer, and the mixture was
pipetted back onto the cells in the 96-well plates in order to lyse
the cells. The following procedures were performed according to
the RNA Cleanup protocol and the RNA were stored at –75◦C.
The RT-qPCR of MNV-1 was performed by the use of
RNA UltraSenseTM One-Step Quantitative RT-PCR System (Life
technologies). The primers and probe sequence of MNV-1 were
previously shown by Baert et al. (2008). Twenty micro liter of
reaction mixture [200 nM each primer, 200 nM probe, 50 nM
ROX (Life technologies)] was added to 5 µl of RNA. The RT-
qPCR assays were performed in an ABI 7300 system (Applied
Biosystems). The amplification profile consisted of 50◦C for
15 min, 95◦C for 2 min and 45 cycles of 95◦C for 15 s and 60◦C
for 30 s.
An absolute quantification of MNV-1 genomic copies was
performed as described by Baert et al. (2008). To obtain
representative positive control standards, the plasmid p20.3
containing a full-length cDNA clone of MNV-1.CW1 (Baert
et al., 2008) was used for the quantifications. Ten-fold serial
dilutions ranging from 106 to 10 copies of plasmids per reaction
were used to prepare the standard curves.
Viral Binding Inhibition Test on Human
NoV VLPs Detected by Fluorescence
Measurement
The HT-29 cells were seeded into 96-well plates at a density of
105 viable cells per well. On the following day, the B. adolescentis
was re-suspended in NoV GI.1 VLP suspension [5µg/ml, in PBS-
0.1% bovine serum albumin (BSA)]. The mixture of bacteria and
VLPs was added onto the cells (50 µl per well) and incubated
for 1 h at room temperature. After washing with PBS for
three times, the cells were fixed with 4% paraformaldehyde, and
stained by anti-VLP rabbit polyclonal antibodies (lp130 for GI.1,
diluted in PBS-0.1% BSA, 1-h incubation at 37◦C) followed by
Alexa Fluor R© 488 Goat Anti-Rabbit IgG (H+L) antibody (Life
Technologies, diluted in PBS-0.1% BSA, 1-h incubation at 37◦C).
Three times washing by PBS was always performed after each
step. The fluorescence was read by a fluorimeter (Fluoroskan,
Thermo Scientific; Ex/Em= 490/525 nm) in arbitrary unit (a.u.).
The binding test of human NoV GI.1 and GII.4 VLPs (anti-
VLP rabbit polyclonal antibodies lp130 for GI.1 and lp132 for
GII.4) on Caco-2 cell were similar with the procedures above
except that the Caco-2 cells were incubated for 21 days post
confluency to be used as differentiated cells.
The binding of NoV GI.1 VLPs to HT-29 cells was also
observed with a fluorescence microscope. The HT-29 cells were
seeded into eight-well Nunc R© Lab-Tek R© Chamber Slide System
(Sigma–Aldrich) at a density of 105 viable cells per well. On the
following day, the binding and staining steps were the same as
described above. After the last washing step (from the secondary
antibody incubation), the upper structure was removed from the
bottom glass slide. The stained cells were mounted on slides
with Vectashield R© (Vector laboratories, Burlingame, CA, USA).
The sealed slides were observed under a Zeiss Axiovert 200
fluorescence microscope.
Data Analysis
Each result was presented as the mean value of three independent
replicates with the standard deviation. Statistical analyses were
performed by Mann–Whitney U test with SPSS 22 for Windows
(SPSS, Inc., Chicago, IL, USA). Significant differences were
considered when P was <0.05.
RESULTS
Effect of B. adolescentis on MNV-1
Infectivity
First of all, after 48 h incubation, the cell viability determined
by neutral red assay showed no significant reduction after
incubation of the RAW 264.7 cells with B. adolescentis (OD540
1.1± 0.1–1.1± 0.2, P > 0.05).
MNV-1 lysate was diluted to a concentration that can form
countable plaques on the six-well plates, and was seeded onto the
cells with or without B. adolescentis. The plaque assay showed that
compared with the negative control (MNV-1 on RAW 264.7 cells
without bacteria), the MNV-1 plaque forming units (PFU) from
cell-culture wells in the presence of B. adolescentis were decreased
significantly from 20± 3–7± 2 PFU/well (Figure 1A, P < 0.05).
It was also noticed that the sizes of the plaques from cells
incubated with B. adolescentis were smaller than the negative
control (examples shown in Figure 1C). The average sizes of
the plaques measured by ImageJ showed that compared with the
negative control (MNV-1 on RAW 264.7 cells without bacteria),
the plaque diameters from cell-culture wells in the presence
of B. adolescentis were decreased significantly from 9.2 ± 2.7–
3.9 ± 0.6 pixel (Figure 1B, P < 0.05). These results indicate that
the effect of B. adolescentis on MNV-1 may occur mainly in the
viral replication phase instead of showing direct virucidal effect
on the MNV-1 or preventing the viruses from binding to the cells.
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FIGURE 1 | MNV-1 multiplication inhibition by B. adolescentis determined by plaque assay. (A) Plaque forming units (PFU) from cell-culture wells with and
without B. adolescentis. Each data point is an average of three independent tests, and each error bar represents the data range. ∗P < 0.05. (B) Plaque diameters
from cell-culture wells with and without B. adolescentis. Each data point is an average of 15 measurements, and each error bar represents the data range.
∗P < 0.05. (C) Plaque appearances from cell-culture wells with and without B. adolescentis.
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Therefore lastly, a viral binding inhibition test was performed
and indeed no significant difference of MNV-1 genomic copies
collected from RAW 264.7 cells between the two groups with
(5.77 ± 0.03 log-genomic copies/ml) and without B. adolescentis
(5.74± 0.01 log-genomic copies/ml) was observed (P > 0.05).
Effect of B. adolescentis on Human NoV
VLPs Cell-Binding Ability
It has been previously reported that both VLPs of human NoV
GI.1 and GII.4 could bind to Caco-2 cells (Tamura et al., 2004)
and VLPs of human NoV GI.1 could bind to HT-29 cells (Rubio-
del-Campo et al., 2014).
The presence of B. adolescentis decreased the binding of
human NoV GI.1 VLPs to Caco-2 cells, measured by fluorescence
intensity, significantly from 45.2 ± 5.0 (negative control without
bacteria) to 33.0 ± 4.6 a.u. (incubation with B. adolescentis;
Figure 2A, P < 0.05).
The fluorescence intensity of human NoV GI.1 VLPs on
HT-29 cells also decreased, although not significantly, from
92.0 ± 25.0 to 52.0 ± 5.0 a.u. by the incubation of B. adolescentis
(Figure 2B, P = 0.05). A visual example detected by fluorescence
microscopy was shown in Figure 2C.
As for human NoV GII.4 VLPs, no significant reduction was
observed for the binding of the VLPs to Caco-2 cells with the
incubation of B. adolescentis (19.0 ± 1.7 to 17.7 ± 0.6 a.u.,
P > 0.05).
DISCUSSION
Currently, the research on the effect of probiotics on NoVs
are still preliminary. On one hand, due to the non-cultivability
of human NoVs, the in vitro studies were conducted with the
use of surrogate viruses [e.g., feline calicivirus (FCV), Aboubakr
et al., 2014; MNV-1 and Tulane virus (TV), Shearer et al.,
2014] and artificially synthesized particles partially mimicking
the viral structures (P-particles, Rubio-del-Campo et al., 2014),
which may introduce gaps from the authentic NoV reactions.
On the other hand, there are an insufficient number of in-
depth studies on this topic before a general conclusion can be
drawn. For instance, it was reported that the fermentation of
Donchimi and oysters could effectively reduce the infectivity
of FCV and MNV-1 (Lee et al., 2012; Seo et al., 2014). The
population of LAB increased largely during the fermentation,
however, it was neither clear on the role that the LAB played
nor the associated mechanisms (Lee et al., 2012; Seo et al.,
2014). For another instance, high infectivity reduction (6 –7-
log reduction) was observed for FCV following co-incubation
with Lactococcus lactis (both bacterial medium filtrate and
cells suspension, Aboubakr et al., 2014). However, the cell-free
supernatant of a commercial probiotic mixture of Lactobacillus
acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum,
Lactobacillus salivarius, and Streptococcus thermophiles indicated
no reduction for the infectivity of MNV and TV (Shearer et al.,
2014). The reasons causing the inconsistence of the studies can be
the differences between both of the studied viruses and bacteria
strains, as well as the experimental settings such as time/sequence
FIGURE 2 | Human NoV GI.1 VLPs binding inhibition by B. adolescents.
(A) Fluorescence measurement in arbitrary unit (a.u.) of human NoV GI.1 VLPs
bound to Caco-2 cells. Each data point is an average of three independent
tests, and each error bar represents the data range. ∗P < 0.05.
(B) Fluorescence measurement in arbitrary unit (a.u.) of human NoV GI.1 VLPs
bound to HT-29 cells. Each data point is an average of three independent
tests, and each error bar represents the data range. (C) Fluorescence
microscope observation of human NoV GI.1 VLPs bound to HT-29 cells.
of addition, comparative ratio of viruses and bacteria, incubation
conditions (time, atmosphere and temperature) and matrices, etc.
In this study, MNV-1 was employed as the surrogate as it was
more persistent than FCV in the fermentation of both Donchimi
and oysters (Lee et al., 2012; Seo et al., 2014). Human NoV VLPs
from GI.1 and GII.4 were used as they could mimic the binding
capacity of two representative NoV genotypes. B. adolescentis
is a recognized probiotics (Lee et al., 1993; Kim et al., 2008)
and has interested dairy manufacturers in producing “therapeutic
fermented milk products” (Arunachalam, 1999; Puniya, 2015).
Also it was reported recently to exhibit antiviral activity against
Coxsackievirus (Kim et al., 2014). The bacterial cells were washed
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with PBS before being added to the viruses and cells in order to
avoid any direct virucidal effect of the bacterial metabolites in the
culture medium, such as organic acids, diacetyl, and bacteriocins.
The bacteria and viruses (MNV-1 and human NoV VLPs) were
co-incubated with the cells as this strategy was shown to be more
effective than pre-treatment of cells, pre-treatment of viruses
(Aboubakr et al., 2014; Rubio-del-Campo et al., 2014), or post-
treatment of cells attached to viruses (Rubio-del-Campo et al.,
2014).
It was demonstrated in this study that the presence of
B. adolescentis could inhibit the multiplication of MNV-1 on
RAW 264.7 cells. Meanwhile, it was shown that this inhibition
effect did not occur on the binding stage of MNV-1 to RAW
264.7 cells. However, in contrast, the presence of B. adolescentis
did decrease the binding of human NoV GI.1 VLPs to both Caco-
2 cells and HT-29 cells. Although based on different models,
these results indicate that the effects of B. adolescentis on different
viruses might vary based on different mechanisms.
It was reported previously that NoV P-particles could bind
to a series of probiotics with varied binding ability, which was
postulated as one of the antiviral mechanisms of the probiotics
(Rubio-del-Campo et al., 2014). However, based on a recent
study of our group (Li et al., 2015), the B. adolescentis strain
used in this study does not express histo-blood group antigen
(HBGA) and could not bind to NoV VLPs of either GI.1 or
GII.4. This result rules out the possibility of direct competition
of B. adolescentis and NoV GI.1VLPs from binding to Caco-2
or HT-29 cells. Instead, as we and others have described a few
bacterial lectins binding to HBGAs (Gilboa-Garber et al., 2011;
Audfray et al., 2012) and Zhong et al. (2004) have reported that
the adhesin of B. adolescentis 1027 could inhibit the adhesion of
Escherichia coli to intestinal epithelial cell line Lovo, we assume
that certain lectins secreted by B. adolescentis could bind to the
HBGAs on the intestinal cell lines and compete with the binding
of NoV GI.1VLPs.
As the binding of human NoV GI.1 VLPs to both Caco-2 cells
and HT-29 cells was decreased in the presence of B. adolescentis,
it is reasonable to assume that the viral multiplication of human
NoV GI.1, if an in vitro model could be established, should
also be decreased in the presence of B. adolescentis. On the
other hand, although no reduction of the binding of human
NoV GII.4 VLPs to Caco-2 cells was observed in the presence
of B. adolescentis, the possibility cannot be ruled out that
B. adolescentis may reduce the viral multiplication of human
NoV GII.4 if an in vitro model could be established, or help
combat NoVs in vivo. The differences observed between the two
strains are not surprising as it is well known that the chemical
structures of the receptor binding interfaces are different between
NoV GI.1 and GII.4 (Tan and Jiang, 2011). However, the exact
molecular mechanisms casing the influence of B. adolescentis on
human NoV VLPs binding to intestinal cell lines still need further
investigation.
CONCLUSION
This study demonstrated the antiviral effect of B. adolescentis
against NoVs. Due to the lack of models to study the infection of
genuine human NoVs, the results were generated from studying
surrogates detected by different methods (infection and binding
of MNV-1 on murine macrophage cell line RAW 264.7and
binding of human NoV VLPs on human intestinal epithelial cell
lines Caco-2 and HT-29). Since the effects of B. adolescentis on
MNV-1 and human NoV VLPs as well as their mechanisms were
indicated to be different, this study shows the importance of
establishing multiplication model for human NoVs in the future.
In addition, more probiotic strains will be tested before a general
conclusion can be drawn on the antiviral effect of probiotics on
NoV infection.
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